Frank T S, Manley S A, Olopade O I, Cummings S, Garber J E, Bernhardt B, Antman K, Russo D, Wood M E, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley P T, Loader S, Offit K, Robson M, Hampel H, Brener D, Winer E P, Clark S, Weber B, Strong L C, Thomas A
Myriad Genetic Laboratories, Salt Lake City, UT 84108, USA.
J Clin Oncol. 1998 Jul;16(7):2417-25. doi: 10.1200/JCO.1998.16.7.2417.
Previous studies of mutations in BRCA1 or BRCA2 have used detection methods that may underestimate the actual frequency of mutations and have analyzed women using heterogeneous criteria for risk of hereditary cancer.
A total of 238 women with breast cancer before age 50 or ovarian cancer at any age and at least one first- or second-degree relative with either diagnosis underwent sequence analysis of BRCA1 followed by analysis of BRCA2 (except for 27 women who declined analysis of BRCA2 after a deleterious mutation was discovered in BRCA1). Results were correlated with personal and family history of malignancy.
Deleterious mutations were identified in 94 (39%) women, including 59 of 117 (50%) from families with ovarian cancer and 35 of 121 (29%) from families without ovarian cancer. Mutations were identified in 14 of 70 (20%) women with just one other relative who developed breast cancer before age 50. In women with breast cancer, mutations in BRCA1 and BRCA2 were associated with a 10-fold increased risk of subsequent ovarian carcinoma (P = .005).
Because mutations in BRCA1 and BRCA2 in women with breast cancer are associated with an increased risk of ovarian cancer, analysis of these genes should be considered for women diagnosed with breast cancer who have a high probability of carrying a mutation according to the statistical model developed with these data.
先前关于BRCA1或BRCA2基因突变的研究使用的检测方法可能低估了实际突变频率,并且在分析女性遗传性癌症风险时采用了异质性标准。
共有238名年龄小于50岁的乳腺癌患者或任何年龄的卵巢癌患者,且至少有一位一级或二级亲属患有上述任何一种疾病,对其进行BRCA1序列分析,随后进行BRCA2分析(27名在BRCA1中发现有害突变后拒绝进行BRCA2分析的女性除外)。结果与个人及家族恶性肿瘤病史相关。
在94名(39%)女性中发现有害突变,其中117名有卵巢癌家族史的女性中有59名(50%),121名无卵巢癌家族史的女性中有35名(29%)。在仅有一位50岁前患乳腺癌的亲属的70名女性中,有14名(20%)发现了突变。在乳腺癌女性中,BRCA1和BRCA2突变与后续卵巢癌风险增加10倍相关(P = .005)。
由于乳腺癌女性中BRCA1和BRCA2突变与卵巢癌风险增加相关,对于根据这些数据建立的统计模型判定携带突变可能性高的乳腺癌确诊女性,应考虑对这些基因进行分析。